![In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution | Journal of Aerosol Medicine and Pulmonary Drug Delivery In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution | Journal of Aerosol Medicine and Pulmonary Drug Delivery](https://www.liebertpub.com/cms/10.1089/jamp.2017.1384/asset/images/medium/figure1.gif)
In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution | Journal of Aerosol Medicine and Pulmonary Drug Delivery
![LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension) LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension)](https://mma.prnewswire.com/media/1472397/eFlow_Partnering_eBase_Controller_Lamira.jpg?p=facebook)
LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension)
![Magnair™ an eFlow® Closed System Nebulizer together with Sunovion's Lonhala™ is the first eFlow technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD) Magnair™ an eFlow® Closed System Nebulizer together with Sunovion's Lonhala™ is the first eFlow technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)](https://mma.prnewswire.com/media/616445/PARI_Pharma_Lonhala_Magnair_Inhalation_Solution.jpg?p=twitter)